News
OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential …
2017-06-01
China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study
On 24 January 2017, OBI Pharma, Inc. (4174) received formal …
2017-01-25
OBI Pharma holds EOP2 meeting with US FDA
OBI Pharma, Inc. has met with the Office of Tissues …
2017-01-20
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with …
2017-01-10
OBI Pharma Awarded Level-A Recognition for TIPS Management
OBI Pharma, Taiwan (4174) announced that it has been awarded …
2016-11-30
OBI Pharma Granted OBI 833 Patents for Taiwan and Australia
OBI Pharma, Taiwan (4174) announced that it has been granted …
2016-11-23
OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO
OBI Pharma is pleased to provide video highlights from the …
2016-10-26
Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine
In response to Next Magazine’s continuous and malicious publication of …
2016-09-06
OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting
Experts Examine the Future of Active Immunotherapy in Oncology and …
2016-09-06
Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”
Some media have reported on Dr. Michael Chang, the Chairman …
2016-09-03